NeoGenomics Highlights ctDNA and NGS Advancements at ESMO 2024
Wednesday, 11 September 2024, 04:06
Overview of Cancer Diagnostics
NeoGenomics is set to present transformative insights into ctDNA and NGS at ESMO 2024, highlighting their significance in enhancing cancer diagnostics.
Importance of ctDNA and NGS
The integration of circulating tumor DNA (ctDNA) analysis with next-generation sequencing (NGS) has revolutionized how oncologists approach cancer care. These technologies allow for:
- Non-invasive testing: Reducing the need for extensive biopsies.
- Real-time monitoring: Tracking treatment response and disease progression.
- Personalized treatment: Tailoring therapies based on genetic mutations present in the tumor.
Future Directions in Cancer Testing
As cancer diagnostics evolve, innovations like these will continue to shape the practice of oncology, providing better tools for clinicians and improved outcomes for patients.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.